In the latest trading session, 0.68 million Context Therapeutics Inc (NASDAQ:CNTX) shares changed hands as the company’s beta touched 2.27. With the company’s most recent per share price at $2.31 changing hands around $0.31 or 15.25% at last look, the market valuation stands at $172.88M. CNTX’s current price is a discount, trading about -19.05% off its 52-week high of $2.75. The share price had its 52-week low at $0.77, which suggests the last value was 66.67% up since then. When we look at Context Therapeutics Inc’s average trading volume, we note the 10-day average is 87370.0 shares, with the 3-month average coming to 182.18K.

Analysts gave the Context Therapeutics Inc (CNTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CNTX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Context Therapeutics Inc’s EPS for the current quarter is expected to be -0.1.

Context Therapeutics Inc (NASDAQ:CNTX) trade information

Instantly CNTX is in green as seen in intraday trades today. With action 12.44%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 103.98%, with the 5-day performance at 12.44% in the green. However, in the 30-day time frame, Context Therapeutics Inc (NASDAQ:CNTX) is 17.60% up. Looking at the short shares, we see there were 1.09 million shares sold at short interest cover period of 3.89 days.

The consensus price target for the stock as assigned by Wall Street analysts is 5.25, meaning bulls need an upside of 56.0% from its recent market value. According to analyst projections, CNTX’s forecast low is 4.5 with 6 as the target high. To hit the forecast high, the stock’s price needs a -159.74% plunge from its current level, while the stock would need to soar -94.81% for it to hit the projected low.

Context Therapeutics Inc (CNTX) estimates and forecasts

Data shows that the Context Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 77.31% over the past 6 months, a 73.33% in annual growth rate that is considerably higher than the industry average of 17.50%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -26.70%. The 2024 estimates are for Context Therapeutics Inc earnings to increase by 77.83%.

CNTX Dividends

Context Therapeutics Inc is expected to release its next quarterly earnings report on 2024-Aug-07.

Context Therapeutics Inc (NASDAQ:CNTX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.45% of Context Therapeutics Inc shares while 76.40% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 77.52%. There are 76.40% institutions holding the Context Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 28.1986% of the shares, roughly 4.5 million CNTX shares worth $9.03 million.

GREAT POINT PARTNERS LLC holds the second largest percentage of outstanding shares, with 13.4999% or 7.42 million shares worth $14.88 million as of 2024-06-30.

Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 3.12 shares estimated at $7.22 million under it, the former controlled 4.17% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.70% of the shares, roughly 1.28 shares worth around $2.95 million.